Insilco molecular docking study of Dihydroisoquinolinium Derivatives as DPP IV Inhibitors in Type II Diabetes Mellitus

  • Posted on: 31 May 2017
  • By: admin

Pharma courses

pharma courses

Magazine Home

June 2017 ARTICLE LIST >>

PharmaTutor (June - 2017)


ISSN: 2347 - 7881
(Volume 5, Issue 6)


Received On: 24/02/2017; Accepted On: 10/03/2017; Published On: 01/06/2017


Amiya Kumar Ghosh*1, Shiladitya Palit2, SaptarshiSamajdar3
1Dept. of Pharmacy, Utkal University, Orissa
2Dept. of Pharmacy, IITBHU
3Centre for Pharmaceutical Sc. And Natural Products, Central University of Punjab



With the spread of western lifestyles, the occurrence of diabetes in the world’s population is rising. Diabetes is a complex metabolic endocrine disorder that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. It is classified into two basic forms Type I and Type II diabetes. A major goal for the treatment of type II diabetes is the enhancement of insulin secretion by pancreatic islet b-cells.



How to cite this article: Ghosh AK, Palit S, Samajdar S; Insilco molecular docking study of Dihydroisoquinolinium derivatives as DPP IV inhibitors in type II Diabetes Mellitus; PharmaTutor; 2017; 5(6);22-28



Download Manuscript PDF